astaxanthine has been researched along with Nerve-Degeneration* in 2 studies
1 review(s) available for astaxanthine and Nerve-Degeneration
Article | Year |
---|---|
Molecular Mechanisms of Astaxanthin as a Potential Neurotherapeutic Agent.
Neurological disorders are diseases of the central and peripheral nervous system that affect millions of people, and the numbers are rising gradually. In the pathogenesis of neurodegenerative diseases, the roles of many signaling pathways were elucidated; however, the exact pathophysiology of neurological disorders and possible effective therapeutics have not yet been precisely identified. This necessitates developing multi-target treatments, which would simultaneously modulate neuroinflammation, apoptosis, and oxidative stress. The present review aims to explore the potential therapeutic use of astaxanthin (ASX) in neurological and neuroinflammatory diseases. ASX, a member of the xanthophyll group, was found to be a promising therapeutic anti-inflammatory agent for many neurological disorders, including cerebral ischemia, Parkinson's disease, Alzheimer's disease, autism, and neuropathic pain. An effective drug delivery system of ASX should be developed and further tested by appropriate clinical trials. Topics: Animals; Anti-Inflammatory Agents; Humans; Nerve Degeneration; Nervous System Diseases; Neurons; Neuroprotective Agents; Xanthophylls | 2021 |
1 other study(ies) available for astaxanthine and Nerve-Degeneration
Article | Year |
---|---|
Astaxanthin Ameliorates Doxorubicin-Induced Cognitive Impairment (Chemobrain) in Experimental Rat Model: Impact on Oxidative, Inflammatory, and Apoptotic Machineries.
Chemobrain refers to a common sequelae experienced by 15-80% of cancer patients exposed to chemotherapeutics. The antineoplastic agent doxorubicin (DOX) has been implicated in a strenuous neurotoxicity manifested as decline in cognitive functions, most probably via cytokine-induced oxidative and nitrosative damage to brain tissues. Astaxanthin (AST), a naturally occurring carotenoid, is reputable for its outstanding antioxidant, anti-inflammatory, and antiapoptotic activities. Therefore, the aim of the current study was to investigate the potential neuroprotective and memory-enhancing effects of AST against DOX-induced behavioral and neurobiological abnormalities. Briefly, AST treatment (25 mg/kg) significantly protected against DOX-induced memory impairment. Furthermore, AST restored hippocampal histopathological architecture, halted DOX-induced oxidative and inflammatory insults, mitigated the increase in acetylcholinesterase activity, and consistently downregulated the overactive apoptotic machineries. In conclusion, these findings suggest that AST offers neuroprotection against DOX-induced cognitive impairment which could be explained at least partly by its antioxidant, anti-inflammatory, and antiapoptotic effects. Topics: Acetylcholinesterase; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Behavior, Animal; Biomarkers; Cognitive Dysfunction; Disease Models, Animal; Doxorubicin; Glial Fibrillary Acidic Protein; Hippocampus; Inflammation; Male; Models, Biological; Motor Activity; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Rats; Xanthophylls | 2018 |